BRPI0417531A - canal de sódio - Google Patents

canal de sódio

Info

Publication number
BRPI0417531A
BRPI0417531A BRPI0417531-0A BRPI0417531A BRPI0417531A BR PI0417531 A BRPI0417531 A BR PI0417531A BR PI0417531 A BRPI0417531 A BR PI0417531A BR PI0417531 A BRPI0417531 A BR PI0417531A
Authority
BR
Brazil
Prior art keywords
sodium channel
polypeptides
nucleic acids
disclosed
methods
Prior art date
Application number
BRPI0417531-0A
Other languages
English (en)
Inventor
Angela Hornsten
Rodrigo Franco
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0417531A publication Critical patent/BRPI0417531A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)

Abstract

"CANAL DE SóDIO". Novos ácidos nucléicos e polipeptídeos de canal de sódio são revelados aqui. Métodos de usar os novos ácidos nucléicos e polipeptídeos são também revelados.
BRPI0417531-0A 2003-12-12 2004-12-10 canal de sódio BRPI0417531A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52940403P 2003-12-12 2003-12-12
PCT/US2004/041668 WO2005059101A2 (en) 2003-12-12 2004-12-10 Novel sodium channel

Publications (1)

Publication Number Publication Date
BRPI0417531A true BRPI0417531A (pt) 2007-03-20

Family

ID=34699976

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417531-0A BRPI0417531A (pt) 2003-12-12 2004-12-10 canal de sódio

Country Status (9)

Country Link
US (1) US20080069773A1 (pt)
EP (1) EP1699914A2 (pt)
JP (1) JP2007524406A (pt)
CN (1) CN101421300A (pt)
AU (1) AU2004299822A1 (pt)
BR (1) BRPI0417531A (pt)
CA (1) CA2549303A1 (pt)
MX (1) MXPA06006602A (pt)
WO (1) WO2005059101A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006101629A2 (en) 2005-02-17 2006-09-28 Vertex Pharmaceuticals Incorporated SODIUM CHANNEL PROTEIN TYPE III α-SUBUNIT SPLICE VARIANT
TW201024733A (en) * 2008-09-26 2010-07-01 Sanofi Aventis Methods for determining sodium-proton-exchanger ligand efficiency
EP2175274A1 (en) * 2008-09-26 2010-04-14 Sanofi-Aventis Methods for determining sodium-proton-exchanger ligand efficiency
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US9078792B2 (en) 2011-06-30 2015-07-14 The Procter & Gamble Company Two-piece wearable absorbent article having advantageous front waist region and landing zone configuration
EA201591754A1 (ru) * 2013-03-14 2016-01-29 Ридженерон Фармасьютикалз, Инк. Человеческие антитела к na1.7
WO2019118779A2 (en) 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096552A1 (fr) * 2000-06-13 2001-12-20 Japan Science And Technology Corporation Canaux sodiques scn1a et scn3a
GB0211833D0 (en) * 2002-05-22 2002-07-03 Univ London Sodium channel regulators and modulators
WO2004050857A2 (en) * 2002-12-04 2004-06-17 Euro-Celtique S.A. Splice variant of human sodium iii channel (hnaiii18)

Also Published As

Publication number Publication date
WO2005059101A2 (en) 2005-06-30
CA2549303A1 (en) 2005-06-30
WO2005059101A3 (en) 2009-04-30
US20080069773A1 (en) 2008-03-20
EP1699914A2 (en) 2006-09-13
MXPA06006602A (es) 2007-01-26
AU2004299822A1 (en) 2005-06-30
JP2007524406A (ja) 2007-08-30
CN101421300A (zh) 2009-04-29

Similar Documents

Publication Publication Date Title
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
ATE365727T1 (de) Epoxyendgruppen-enthaltende polythioether
ATE500323T1 (de) Subtilisin-variante
ATE421973T1 (de) Inzektizide proteinen von bacillus thuringiensis
BR0215405A (pt) Composições e processos de uso de collajolie
ITRM20030376A1 (it) Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
DE69919700D1 (de) Überbrückte indenopyrrolocarbazole
EP1641910A4 (en) GLUCANASES, THESE CODING NUCLEIC ACIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
BRPI0413449A (pt) compostos de quinoxalina
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
NO20044916L (no) Preparater av sulfinylacetamid
EP1443860A4 (en) CARBOCYANINE DYES FOR TANDEM, PHOTODIAGNOSTIC AND THERAPEUTIC APPLICATIONS
BR0316324A (pt) Polipeptìdeos e conjugados de interferon-alfa
EP1509226A4 (en) SMALL MOLECULAR INHIBITORS OF THE HER2 EXPRESSION
EP1578787A4 (en) NEW CHI-CONOTOXINPEPTIDES (-II)
ITMI20021038A0 (it) Disposizione di elettrodi
BR0316544A (pt) Compostos calcilìticos
WO2005059101A3 (en) Novel sodium channel
ATA3922001A (de) Medizinische elektrode
BR0014068A (pt) Polipeptìdeos de subunidades de canais de cálcio de alfa2delta-2, alfa2delta-3 ou alfa2beta-4 secretados solúveis e testes de seleção usando os mesmos
DE60124148D1 (de) Kalzilytische verbindungen
ATE505538T1 (de) Dna-vektoren
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
ATE506433T1 (de) Prozessierung von peptiden und proteinen
NO20053829D0 (no) Fremgangsmate og intermediater for fremstilling av olanzapin.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.